Pfizer Inc. [NYSE: PFE] loss -0.35% or -0.14 points to close at $39.81 with a heavy trading volume of 16882569 shares. The company report on May 24, 2021 that Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults.
Pfizer Inc. (NYSE: PFE) announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA). The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines.
The trial will include 600 adults who will be recruited from the pivotal Phase 3 Pfizer-BioNTech COVID-19 Vaccine trial and will have received their second dose of the vaccine at least six months prior to entering the coadministration study. The participants are being randomized to one of three groups:.
It opened the trading session at $40.08, the shares rose to $40.14 and dropped to $39.775, the range by which the price of stock traded the whole day. The daily chart for PFE points out that the company has recorded 10.00% gains over the past six months. However, it is still -32.88% lower than its most recent low trading price.
If we look at the average trading volume of 29.78M shares, PFE reached to a volume of 16882569 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $42.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 06, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Sector Perform. The new note on the price target was released on April 07, 2021, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise to $41, while DZ Bank analysts kept a Buy rating on PFE stock. On December 16, 2020, analysts decreased their price target for PFE shares from 43 to 42.
The Average True Range (ATR) for Pfizer Inc. is set at 0.68, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 4.82. The Price to Book ratio for the last quarter was 3.24, with the Price to Cash per share for the same quarter was set at 2.43. Price to Free Cash Flow for PFE in the course of the last twelve months was 45.12 with Quick ratio for the last quarter at 1.20.
Trading performance analysis for PFE stock
Pfizer Inc. [PFE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.75. With this latest performance, PFE shares gained by 2.97% in over the last four-week period, additionally plugging by 10.00% over the last 6 months – not to mention a rise of 12.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 58.92, with the RSI for the last a single of trading hit 54.78, and the three-weeks RSI is set at 60.47 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 37.92, while it was recorded at 39.95 for the last single week of trading, and 37.10 for the last 200 days.
Pfizer Inc. [PFE]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +21.52 and a Gross Margin at +71.21. Pfizer Inc.’s Net Margin is presently recorded at +16.67.
Return on Total Capital for PFE is now 8.14, given the latest momentum, and Return on Invested Capital for the company is 6.93. Return on Equity for this stock inclined to 11.05, with Return on Assets sitting at 4.34. When it comes to the capital structure of this company, Pfizer Inc. [PFE] has a Total Debt to Total Equity ratio set at 65.26. Additionally, PFE Total Debt to Total Capital is recorded at 39.49, with Total Debt to Total Assets ending up at 26.76. Long-Term Debt to Equity for the company is recorded at 60.48, with the Long-Term Debt to Total Capital now at 36.60.
Reflecting on the efficiency of the workforce at the company, Pfizer Inc. [PFE] managed to generate an average of $88,981 per employee. Receivables Turnover for the company is 5.03 with a Total Asset Turnover recorded at a value of 0.26.Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.50.
Pfizer Inc. [PFE]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Pfizer Inc. posted 0.78/share EPS, while the average EPS was predicted by analysts to be reported at 0.66/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 18.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to 12.57%.
An analysis of insider ownership at Pfizer Inc. [PFE]
There are presently around $146,032 million, or 66.80% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 450,914,119, which is approximately 0.66% of the company’s market cap and around 0.04% of the total institutional ownership; BLACKROCK INC., holding 405,733,970 shares of the stock with an approximate value of $16.15 billion in PFE stocks shares; and STATE STREET CORP, currently with $10.94 billion in PFE stock with ownership of nearly -1.679% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 1,388 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 143,767,963 shares. Additionally, 1,227 investors decreased positions by around 175,625,607 shares, while 201 investors held positions by with 3,348,841,449 shares. The mentioned changes placed institutional holdings at 3,668,235,019 shares, according to the latest SEC report filing. PFE stock had 159 new institutional investments in for a total of 18,235,320 shares, while 137 institutional investors sold positions of 13,609,093 shares during the same period.